Skip to main content
. 2017 Oct 9;8(60):101784–101794. doi: 10.18632/oncotarget.21695

Figure 7. Inhibitory effect of metformin on peritendinous fibrosis was blocked by Compound C.

Figure 7

All the NIH/3T3 fibroblasts were pretreated with Compound C (1 μM) for 24 h before further treated with TGF-β1 (2 ng/ml) and/or metformin (5 mM). (A) The real-time PCR analysis showed that metformin was unbale to down-regulated the mRNA levels of col1a1, col3a1 and α-SMA in fibroblasts pretreated with Compound C. (B) The western blot analysis showed that metformin was unbale to down-regulated the protein levels of col1a1, col3a1 and α-SMA in fibroblasts pretreated with Compound C. Compound C abolished the down-regulation of metformin on SMAD and MAPK signaling pathways. Data are expressed as means ± SEM. * P < 0.05; ** P < 0.01. N.S. not significant.